• Induced Model LPS responses, LPS/D-GAL, hepatic failure
  • Performed on TNF, TNFR1
  • Readouts Cytokine levels, Lethality, ALT activity

TNFR1 as a therapeutic target

TNF is a key regulator of inflammation and its blockade has proven to be very successful treatment for a variety of inflammatory disorders including arthritis, inflammatory bowel disease, psoriasis and others. However, TNF blockade also affects the physiological functions of TNF with a main drawback being the increased susceptibility to infections. Research work has shown that uncoupling the TNFR1-mediated pro-inflammatory effects of TNF from its TNFR2-mediated immunosuppressive properties  would be an advantageous treatment approach.

In recent years, TNFR1 has emerged as an attractive target for the detrimental effects of the TNF signalling pathway and various TNFR1 inhibitors are currently in clinical including ATROSAB and GSK1995057.

The humanized TNFR1 mouse models

Biomedcode offers the unique hTNFR1KI mouse model, a mouse that expresses human TNFR1 in the absence of its mouse counterpart. In combination with induced or spontaneous disease models, it offers a unique tool for the efficacy evaluation of human therapeutics targeting the TNFR1.

Preclinical Platforms for the evaluation of TNFR1 targeting therapeutics

Model Duration Read outs
Experimental Autoimmune Encephalomyelitis

Mog-induced EAE

25-30 days -Weight
-Clinical Scoring
Spontaneous Arthritis 



12 weeks
4-8 weeks
-Clinical Scoring
Induced Arthritis 

Collagen Antibody Induced Arthritis (CAIA)

2 weeks -Weight
-Clinical Scoring
-Serum Cytokine levels
Acute Inflammation


24 hours -Serum cytokine levels-Survival